Monday, July 18, 2016

Company Update (NASDAQ:GILD): Gilead receives approval in Canada for EPCLUSA™ (sofosbuvir/velpatasvir), the first once-daily pan-genotypic (genotypes 1-6) single tablet regimen for the treatment of chronic hepatitis C

with a current market cap of $ecting to http://finance.ya, finished yesterday at $. During today’s session, GILD traded between $ and has traded between $ over the past 12 months.
Priced at x this year’s forecasted earnings, GILD shares are relatively inexpensive compared to the industry’s x forward p/e ratio.
In a review of the consensus earnings estimate this quarter, 0 sell-side analysts are looking at $ per share, which would be $0.00 worse than the year-ago quarter and a $0.00 sequential decrease. In looking at the bigger picture, the full-year EPS estimate of $ would be a $0.00 worse when compared to the previous year’s annual results. The quarterly earnings estimate is predicated on a consensus revenue forecast of $0.00 . If reported, that would be a 0.00% decrease over the year-ago quarter.
Recently, d GILD from to (/fin). Previously, d GILD from to . Investors should keep in mind is that the average price target is $, which is 0.00% below where the stock opened this morning.

No comments:

Post a Comment